Unite your EDC and eCOA solutions natively. Capture real-time toxicity and QoL data, handle mid-study amendments without downtime, and get to first patient in under 4 weeks.
In oncology, patient safety and dose modifications depend on real-time data. But legacy systems force you to capture objective clinical data in one system and subjective quality-of-life data in another.
That integration tax shows up as real operational costs every day:
With Castor, EDC and eCOA run on the exact same database. No swivel-chair data management. No reconciliation lag.
One unified view of every patient, updated the moment data is submitted.
For oncology teams in fast-moving biotech clinical trials, that difference is a dose cycle.
Three capabilities define why oncology teams move to Castor from legacy two-vendor architectures.
When an oncology patient logs a Grade 3 toxicity event at home, investigators should not have to wait for a system sync to act on it. Castor ePRO feeds directly into the eCRF — the same database, not a connected one.
Investigators see QoL and adverse event data the moment it is submitted. Dose modification decisions for the next cycle can be made immediately, not after the next scheduled data sync.
Oncology protocols change. Basket trials add cohorts. Adaptive designs modify dosing arms. Regulatory feedback requires CRF updates mid-study. Legacy enterprise EDC systems take weeks to revalidate after a protocol change.
Castor’s agile architecture launches 90% of studies in under 4 weeks. Mid-study amendments deploy without downtime, without a full rebuild, and without waiting in a vendor queue. Mid-study amendments include patient re-consenting workflows, so amended protocols reach enrolled patients without a separate eConsent process.
Oncology patients carry immense physical and emotional burdens. Their clinical trial software should not add to it. Castor’s patient app is designed for ease, not for clinical data managers who assume patients will tolerate difficult tools.
We will build a real oncology study in front of you, including mid-study amendment, ePRO setup, and toxicity reporting. It takes 15 minutes.
From agile biotech interventional trials to massive global registries, Castor handles the full spectrum of modern oncology data management.
For oncology teams building real-world evidence programmes alongside their interventional trials, Castor Catalyst bridges the gap between interventional data capture and registry-grade evidence generation.
Over 1.62 million data points captured for over 21,000 patients at Erasmus MC, demonstrating Castor’s ability to scale to large-volume observational oncology programmes without custom infrastructure.
Nearly 5,000 patients captured at a single centre (Radboud UMC), proving Castor can handle high-volume single-site oncology registries with complex longitudinal data requirements.
A factual overview for buyers evaluating Castor against legacy enterprise platforms. All claims are based on publicly available information as of April 2026. See the full Castor vs. Medidata comparison.
| Feature | Castor | Medidata Rave EDC | Veeva Vault EDC | Clario / IQVIA eCOA |
|---|---|---|---|---|
| EDC and eCOA in one system | ✓ Native — same database | ✗ Requires separate eCOA vendor | ✗ Requires separate eCOA vendor | ▬ eCOA only — needs EDC |
| Deployment time | Under 4 weeks (90% of studies) | 12 to 16+ weeks | 8 to 12+ weeks | Varies — add to EDC timeline |
| Mid-study amendments | Zero downtime | Weeks, full revalidation required | Moderate, depends on configuration | eCOA-side only |
| Patient ePRO app | Consumer-grade BYOD app | Available as separate module | Limited native ePRO | Core strength — device or BYOD |
| ePRO compliance rate | 95%+ (oncology QoL endpoints) | Not published | Not published | High — core competency |
| Regulatory compliance | 21 CFR Part 11, ICH E6(R3), GDPR, HIPAA | 21 CFR Part 11, GDPR | 21 CFR Part 11, GDPR | 21 CFR Part 11, GDPR |
| Best fit for | Biotech and mid-pharma teams running fast-moving oncology trials | Large pharma, NCI trials, enterprise scale | Enterprise pharma, Veeva ecosystem users | Trials requiring specialist standalone eCOA |
All competitor information is based on publicly available data as of April 2026. Castor does not claim to be superior in all contexts. Medidata Rave has a longer regulatory submission track record with FDA, EMA, and PMDA that is material for large pharma organisations standardised on its workflows. Verify current capabilities directly with each vendor.
Every oncology study on Castor operates within a fully validated, regulation-ready environment. No separate compliance implementation required.
| Standard | What it means for your oncology trial |
|---|---|
| FDA 21 CFR Part 11 | Full electronic records and signature compliance — required for FDA submission of oncology trial data |
| ICH E6(R3) GCP | Good Clinical Practice aligned — all data handling meets international GCP standards for oncology research |
| GDPR and HIPAA | Patient data handling compliant across EU and US jurisdictions — required for global oncology trials with sites in multiple regions |
| FDA PRO Guidance (2009) | Patient-reported outcome measures collected via Castor ePRO meet FDA guidance for oncology label claims |
| EORTC and ASCO PRO standards | ePRO instruments configured in line with EORTC and ASCO recommendations for oncology QoL endpoint collection in clinical trials |
| ISO 27001 | Information security management system certified — data security audited to international standard |
Castor natively unites EDC and eCOA in a single database, eliminating the integration tax that comes with running separate systems from vendors like Medidata and Clario. Clinical teams get one login, one database, and real-time visibility into both objective clinical data and patient-reported outcomes. There are no sync delays, no reconciliation steps, and no separate vendor relationships to manage.
Castor ePRO is built natively into the EDC, not connected via an API. When an oncology patient logs a Grade 3 toxicity event at home or completes a QoL assessment (EORTC QLQ-C30, FACT), that data appears instantly in the eCRF. Investigators can review it in real time and make dose modification decisions for the next treatment cycle without waiting for a system sync.
90% of Castor studies launch in under 4 weeks. This compares to the 12 to 16 week standard deployment timeline from large enterprise EDC vendors. For biotech teams racing to first patient in, this difference is material and can determine whether a competitive trial opening is captured or missed.
Yes. Castor’s architecture supports mid-study amendments without downtime or full system rebuilds, keeping adaptive, basket, and umbrella trials on schedule when protocols change. Unlike legacy enterprise systems that require extended revalidation periods, Castor changes go live without stopping the trial.
Yes. Castor provides 190+ out-of-the-box oncology PRO instruments including EORTC QLQ-C30 and FACT, enabling QoL data capture natively within the EDC platform without a separate eCOA system.* Sponsor licensing is required for certain proprietary PRO instruments.
Both platforms handle complex oncology data at scale. Key differences: Castor deploys in under 4 weeks vs. Medidata’s 12+ week standard, and Castor’s ePRO is native to the EDC with no integration required. Medidata is the longstanding enterprise standard for large pharma and NCI trials, with a longer regulatory submission track record with FDA, EMA, and PMDA. Castor delivers comparable capability with faster deployment and a unified data model, making it particularly well-suited for biotech clinical trials running Phase I to III programmes.
Yes. Castor is fully compliant with FDA 21 CFR Part 11 (electronic records and signatures), aligned with ICH E6(R3) Good Clinical Practice standards, and meets GDPR and HIPAA data handling requirements across EU and US jurisdictions.
Castor supports the full range of oncology study types: Phase I, II, and III interventional trials, adaptive and basket trials, observational studies, and post-approval registries. Active oncology studies include complex biotech interventional trials, large observational registries capturing millions of data points, and multi-site global studies across 2,100+ sites. Real-world evidence programmes and oncology registries are also supported natively.